[{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Piper Sandler"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Financing","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Piper Sandler"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"GDA-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Gamida Cell
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
